COMBINATION THERAPY FOR PROSTATE CANCER

摘要

The present application demonstrates that HDAC inhibitors can be used in combination with IGF-1R inhibitors and mTOR inhibitors to treat prostate cancer. Combinations of the compounds, with or without HDAC inhibitors, and with or without androgen ablation therapy, can also be used, if indicated. The invention therefore provides methods of treatment and pharmaceutical compositions.